Healthcare

Genetic Signatures Limited (ASX:GSS) rose 7.94% to AUD 0.068, although the shares remain about 77% lower over one year. The company is valued near AUD 15.5mn. TheInvestmentcase remains centred on whether its molecular-diagnostics platform can achieve commercial scale in the United States while reducing …

Chimeric Therapeutics Limited (ASX:CHM) rose 8.33% to AUD 0.02, but the share price remains about 94% lower over one year. TheMarket Capitalisationis close to AUD 1.2mn, reflecting substantial uncertainty around funding, portfolio strategy and the next phase of clinical development. The company has been …

Noxopharm Limited (ASX:NOX) rose 9.52% to AUD 0.092, valuing the clinical-stage biotechnology company at about AUD 28.3mn. The shares remain around 16% lower over one year. The currentInvestmentcase rests on a research pipeline spanning oncology and inflammation, with preclinical validation still playing a central …

INVEX Therapeutics Ltd (ASX:IXC) rose 18.18% to AUD 0.13, extending its one-year gain to about 24%. The company remains a very small biotechnology stock with aMarket Valuenear AUD 9.8mn, and turnover of roughly AUD 16,000 underlines the limitedLiquiditybehind the move. No fresh price-sensitive update …

Island Pharmaceuticals Limited (ASX:ILA) has commissioned a second manufacturing campaign for GMP-grade Galidesivir, expanding the company’s available antiviral inventory as it progresses its outbreak response and biodefence strategy.

Nyrada Inc (ASX:NYR) has reported positive findings from a preclinical study evaluating its lead candidate Xolatryp® in protecting cardiac function against doxorubicin-induced cardiotoxicity.

The contract covers what the company describes as its 'Full Stack + 1' offering, comprising Visage 7 Viewer, Visage 7 Workflow and Visage 7 Open Archive, together with Visage 7 Cardiology Imaging, providing a single, unified enterprise imaging platform. The agreement also includes migration …